Følg
Constantine Tam
Constantine Tam
Ukendt tilknytning
Bekræftet mail på tpg.com.au
Titel
Citeret af
Citeret af
År
Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, ...
New England Journal of Medicine 380 (1), 45-56, 2019
18502019
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ...
New England Journal of Medicine 371 (3), 213-223, 2014
16532014
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ...
New England Journal of Medicine 373 (25), 2425-2437, 2015
13342015
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
CS Tam, S O'Brien, W Wierda, H Kantarjian, S Wen, KA Do, DA Thomas, ...
Blood, The Journal of the American Society of Hematology 112 (4), 975-980, 2008
8682008
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
PA Thompson, CS Tam, SM O’Brien, WG Wierda, F Stingo, W Plunkett, ...
Blood, The Journal of the American Society of Hematology 127 (3), 303-309, 2016
5122016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
S O'Brien, JA Jones, SE Coutre, AR Mato, P Hillmen, C Tam, A Österborg, ...
The Lancet Oncology 17 (10), 1409-1418, 2016
3312016
Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma
CS Tam, MA Anderson, C Pott, R Agarwal, S Handunnetti, RJ Hicks, ...
New England journal of medicine 378 (13), 1211-1223, 2018
3172018
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
JF Seymour, S Ma, DM Brander, MY Choi, J Barrientos, MS Davids, ...
The Lancet Oncology 18 (2), 230-240, 2017
3142017
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
JR McMullen, EJH Boey, JYY Ooi, JF Seymour, MJ Keating, CS Tam
Blood, The Journal of the American Society of Hematology 124 (25), 3829-3830, 2014
2922014
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
M Levade, E David, C Garcia, PA Laurent, S Cadot, AS Michallet, ...
Blood, The Journal of the American Society of Hematology 124 (26), 3991-3995, 2014
2722014
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic LeukemiaBCL2 Gly101Val Causes …
P Blombery, MA Anderson, J Gong, R Thijssen, RW Birkinshaw, ...
Cancer discovery 9 (3), 342-353, 2019
2532019
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ...
Blood, The Journal of the American Society of Hematology 132 (23), 2446-2455, 2018
2452018
Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
CS Tam, R Bassett, C Ledesma, M Korbling, A Alousi, C Hosing, ...
Blood, The Journal of the American Society of Hematology 113 (18), 4144-4152, 2009
2412009
Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia
MA Dimopoulos, A Tedeschi, J Trotman, R García-Sanz, D Macdonald, ...
New England journal of medicine 378 (25), 2399-2410, 2018
2402018
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
MA Anderson, J Deng, JF Seymour, C Tam, SY Kim, J Fein, L Yu, ...
Blood, The Journal of the American Society of Hematology 127 (25), 3215-3224, 2016
2402016
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
JR Brown, P Hillmen, S O’Brien, JC Barrientos, NM Reddy, SE Coutre, ...
Leukemia 32 (1), 83-91, 2018
2192018
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
S Kamel, L Horton, L Ysebaert, M Levade, K Burbury, S Tan, ...
Leukemia 29 (4), 783-787, 2015
2182015
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
MA Dimopoulos, J Trotman, A Tedeschi, JV Matous, D Macdonald, C Tam, ...
The Lancet Oncology 18 (2), 241-250, 2017
215*2017
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ...
American journal of hematology 94 (12), 1353-1363, 2019
2102019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
CS Tam, J Trotman, S Opat, JA Burger, G Cull, D Gottlieb, R Harrup, ...
Blood, The Journal of the American Society of Hematology 134 (11), 851-859, 2019
1942019
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–20